GSK UK Insists on Termination of Healthcare Products Distribution in Nigeria

GSK UK Insists on Termination of Healthcare Products Distribution in Nigeria

GSK UK Group has said that its earlier decision to cease commercialization of its prescription medicines and vaccines in Nigeria through the GSK local operating companies and the planned transition to a third-party direct distribution model for its pharmaceutical products, remained unchanged.


Company Secretary, Fred Ichekwai and Communications and Government Affairs Director, Omongiade Ehighebolo, made the emphasis in a letter they co-sigbed and issued recently.
Part of the letter read: “In our recently published Q2 results we disclosed that the GSK UK Group has informed GlaxoSmithKline Consumer Nigeria plc of its strategic intent to cease commercialization of its prescription medicines and vaccines in Nigeria through the GSK local operating companies and transition to a third-party direct distribution model for its pharmaceutical products. The Haleon Group has also separately informed the Board of its intent to terminate its distribution agreement in the coming months and to appoint a third-party distributor in Nigeria for the supply of the consumer healthcare products.
For the above reasons, and having, together with GSK UK, evaluated various other options, the Board of GlaxoSmithKline Consumer Nigeria Plc has concluded that there is no alternative but to cease operations.”


The letter further said: “Today we are briefing our employees who we will treat fairly, respectfully and with care meeting all applicable legal and consultation requirements. The Board is conscious that shareholders will have many questions; we have been working assiduously with our largest shareholder and local advisors to agree next steps and we intend shortly to submit to the Securities and Exchange Commission “SEC” a draft Scheme of Arrangement which may, if approved, see shareholders other than GSK UK receive an accelerated cash distribution and return of capital. The Board acknowledges the support of the GSK Group in its intentions to make this possible, full details of which we hope to publish shortly. In the meantime, however, we cannot give you assurance of the final terms of any scheme, or that any scheme will be approved by the SEC or by shareholders.”
They advised shareholders to seek professional advice and continue to exercise caution when dealing in the company’s shares until a further announcement is made.

Related Articles